Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The target complex described refers to three critical enzymes of the SARS-CoV-2 virus: the 3-chymotrypsin-like protease (3CLpro or Mpro), the papain-like protease (PLpro), and the helicase (nsp13). 3CLpro (nsp5) and PLpro (a domain of nsp3) are essential for the proteolytic processing of the viral polyproteins pp1a and pp1ab into functional non-structural proteins required for the viral replication-transcription complex (UniProt P0DTD1; PubMed: 32404437). PLpro additionally facilitates immune evasion by cleaving ubiquitin and ISG15 from host proteins, thereby antagonizing the innate immune response (PubMed: 32726803). The helicase (nsp13) is a highly conserved enzyme that unwinds double-stranded RNA in an ATP-dependent manner, a process vital for viral genome replication (PubMed: 32807195). Quercetin, a natural flavonoid, has been identified through in silico and in vitro studies as a potential multi-target inhibitor capable of binding to the active sites of these enzymes, particularly 3CLpro, to disrupt viral activity (PubMed: 33034336). This entry is marked as incorrect because it combines three distinct viral targets and a specific ligand (quercetin) into a single target designation.
Quercetin acts as a multi-target inhibitor that binds to the active sites or allosteric pockets of 3CLpro, PLpro, and the helicase (nsp13), thereby inhibiting viral polyprotein processing and RNA replication.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SARS-CoV-2 3-chymotrypsin-like protease, papain-like protease, and helicase (3CLpro, PLpro, and nsp13).